Zehao Zheng
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Systemic Treatment Patterns and Clinical Outcomes in Hepatocellular Carcinoma: A Multicenter Real-World Study from China (STAR-HCC).
Journal: JHEP reports : innovation in hepatology
Published: March 21, 2026
Adjuvant systemic therapy versus active surveillance after resection following conversion therapy for hepatocellular carcinoma: a propensity score matched study.
Journal: BMC medicine
Published: March 08, 2026
DLGAP5 regulates malignancy and lenvatinib sensitivity of hepatocellular carcinoma through AKT/mTOR/NF-κB pathway.
Journal: European journal of medical research
Published: August 04, 2025
Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma.
Journal: Frontiers in immunology
Published: September 13, 2024
FOLFOX-Based Hepatic Arterial Infusion Chemotherapy with Sequential Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Large Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Study.
Journal: Journal of hepatocellular carcinoma
Published: September 10, 2024
Assessment of Tumor Burden Score as a Feasible and Reliable Tool for Prognosis Prediction for Hepatocellular Carcinoma Undergoing Hepatectomy: A Multicenter, Retrospective Study.
Journal: Journal of hepatocellular carcinoma
Published: July 27, 2024
Leveraging machine learning and single-cell RNA sequencing strategies to develop a risk prognosis scoring based on liquid-liquid phase separation feature genes in pediatric hepatoblastoma.
Journal: Computers in biology and medicine
Published: February 29, 2024
A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapy.
Journal: Cancer immunology, immunotherapy : CII
Published: February 23, 2024
Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors.
Journal: International journal of surgery (London, England)
Published: December 11, 2023
Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma.
Journal: Clinical immunology (Orlando, Fla.)
Published: October 21, 2022
Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma-A Multicentre Experience.
Journal: Journal of inflammation research
Published: June 10, 2022
Development and Validation of a Novel Mitochondrion and Ferroptosis-Related Long Non-Coding RNA Prognostic Signature in Hepatocellular Carcinoma.
Journal: Frontiers in cell and developmental biology
Published: December 28, 2021
Last Updated: 09/26/2026